Multitarget mechanism of MYC inhibition by the bacterial lon protease in disease DOI Creative Commons
Inès Ambite,

Murphy Lam Yim Wan,

Tran Thi Hien

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 25, 2025

Abstract Identifying specific inhibitors of the MYC oncogene has been challenging, due to off target effects associated with inhibition. This study investigated how recombinant Escherichia coli Lon protease (rLon), which targets in human cells, inhibits over-activation models infection and cancer. In silico predictions identified peptide domains bacterial that affinity these peptides for was by surface plasmon resonance. The N-terminal domain rLon shown interact C-terminal, leucine zipper MAX prevent MYC/MAX dimerization. Furthermore, targeted degraded c-MYC vitro cellular models, through peptidase domain. a model kidney infection, treatment prevented, c-MYC, N-MYC L-MYC over-expression, MYC-dependent gene expression, specifically renal toxicity genes pathology, suggesting recognizes corrects dysregulation this disease. findings describe multitarget mechanism inhibition rLon, combined achieved domains, targeting different epitopes functions, no evidence or detrimental on homeostatic expression.

Language: Английский

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion DOI
Renumathy Dhanasekaran, Anja Deutzmann, Wadie D. Mahauad‐Fernandez

et al.

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 19(1), P. 23 - 36

Published: Sept. 10, 2021

Language: Английский

Citations

564
Mesenchymal stem/stromal cells in cancer therapy DOI Creative Commons

Tianxia Lan,

Min Luo,

Xiawei Wei

et al.

Journal of Hematology & Oncology, Journal Year: 2021, Volume and Issue: 14(1)

Published: Nov. 17, 2021

Abstract The multipotent mesenchymal stem/stromal cells (MSCs), initially discovered from bone marrow in 1976, have been identified nearly all tissues of human body now. multipotency MSCs allows them to give rise osteocytes, chondrocytes, adipocytes, and other lineages. Moreover, armed with the immunomodulation capacity tumor-homing property, are special relevance for cell-based therapies treatment cancer. However, hampered by lack knowledge about controversial roles that MSC plays crosstalk tumors, limited progress has made regard translational medicine. Therefore, this review, we discuss prospects MSC-associated anticancer strategies light therapeutic mechanisms signal transduction pathways. In addition, clinical trials designed appraise efficacy safety MSC-based will be assessed according published data.

Language: Английский

Citations

218
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies DOI Creative Commons
Seyed Esmaeil Ahmadi,

Samira Rahimi,

Bahman Zarandi

et al.

Journal of Hematology & Oncology, Journal Year: 2021, Volume and Issue: 14(1)

Published: Aug. 9, 2021

Abstract MYC oncogene is a transcription factor with wide array of functions affecting cellular activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to the multi-functionality MYC, its expression regulated at multiple levels. Deregulation this can give rise variety cancers. In review, regulation mechanisms by which adjusts implication in hematologic malignancies are summarized. Further, we also discuss potential inhibitors that could be beneficial for treating malignancies.

Language: Английский

Citations

141
Burkitt lymphoma DOI
Cristina López, Birgit Burkhardt, John K. C. Chan

et al.

Nature Reviews Disease Primers, Journal Year: 2022, Volume and Issue: 8(1)

Published: Dec. 15, 2022

Language: Английский

Citations

80
Berberine is a suppressor of Hedgehog signaling cascade in colorectal cancer DOI
Qiang Sun, Tao Qiu,

Tianqi Ming

et al.

Phytomedicine, Journal Year: 2023, Volume and Issue: 114, P. 154792 - 154792

Published: March 30, 2023

Language: Английский

Citations

50
Targeted therapy for osteosarcoma: a review DOI
Shizhe Li, He Zhang, Jinxin Liu

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2023, Volume and Issue: 149(9), P. 6785 - 6797

Published: Feb. 18, 2023

Language: Английский

Citations

47
Combinatorial strategies to target RAS-driven cancers DOI
Naiara Perurena, Lisa Situ, Karen Cichowski

et al.

Nature reviews. Cancer, Journal Year: 2024, Volume and Issue: 24(5), P. 316 - 337

Published: April 16, 2024

Language: Английский

Citations

30
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products DOI Creative Commons

Ka Iong Chan,

Siyuan Zhang, Guodong Li

et al.

Aging and Disease, Journal Year: 2024, Volume and Issue: 15(2), P. 640 - 640

Published: Jan. 1, 2024

Various diseases, including cancers, age-associated disorders, and acute liver failure, have been linked to the oncogene, MYC. Animal testing clinical trials shown that sustained tumor volume reduction can be achieved when MYC is inactivated, different combinations of therapeutic agents inhibitors are currently being developed. In this review, we first provide a summary multiple biological functions oncoprotein in cancer treatment, highlighting equilibrium points MYC/MAX, MIZ1/MYC/MAX, MAD (MNT)/MAX complexes further potential treatment could used restrain oncogene expression its tumorigenesis. We also discuss multifunctional capacity various cellular processes, influences on immune response, metabolism, cell cycle, apoptosis, autophagy, pyroptosis, metastasis, angiogenesis, multidrug resistance, intestinal flora. Moreover, summarize therapy patent landscape emphasize as druggable target, using herbal medicine modulators. Finally, describe pending challenges future perspectives biomedical research, involving development approaches modulate or targeted genes. Patients with cancers driven by signaling may benefit from therapies targeting these pathways, which delay cancerous growth recover antitumor responses.

Language: Английский

Citations

20
Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways DOI Open Access
Mário Šereš,

Katarina Spacayova,

Zdena Sulová

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 248 - 248

Published: Jan. 14, 2025

The epidermal growth factor receptor (EGFR) regulates gene expression through two primary mechanisms: as a in the nucleus, where it translocates upon binding its ligand, or via intrinsic tyrosine kinase activity cytosol, modulates key signaling pathways such RAS/MYC, PI3K, PLCγ, and STAT3. During tumorigenesis, these become deregulated, leading to uncontrolled proliferation, enhanced migratory metastatic capabilities, evasion of programmed cell death, resistance chemotherapy radiotherapy. RAS MYC oncogenes are pivotal driving processes apoptosis, replicative immortality, cellular invasion metastasis, metabolic reprogramming. These subject regulation by range epigenetic post-transcriptional modifications. This review focuses on deregulation EGFR, RAS, caused (epi)genetic alterations post-translational It also explores therapeutic potential targeting regulatory proteins, emphasizing importance phenotyping neoplastic tissues inform treatment cancer.

Language: Английский

Citations

3
Beyond small molecules: advancing MYC-targeted cancer therapies through protein engineering DOI
Rama Edaibis, Raneem Akel,

Jumi A. Shin

et al.

Transcription, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 19

Published: Jan. 29, 2025

Protein engineering has emerged as a powerful approach toward the development of novel therapeutics targeting MYC/MAX/E-box network, an active driver >70% cancers. The MYC/MAX heterodimer regulates numerous genes in our cells by binding Enhancer box (E-box) DNA site and activating transcription downstream genes. Traditional small molecules that inhibit MYC face significant limitations include toxic effects, drug delivery challenges, resistance. Recent advances protein offer promising alternatives creating protein-based drugs directly disrupt dimerization interface and/or MYC/MAX's to specific targets. Designed proteins like Omomyc, DuoMyc, ME47, MEF, Mad activity through dimerization, sequestration, DNA-binding mechanisms. Compared molecules, these engineered can superior specificity efficacy provide potential pathway for overcoming traditional cancer therapies. success highlights importance developing treatments.

Language: Английский

Citations

2